P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial,Tiffany Poon,Meghan Rourke,Stacey Chuma,Janet Kunsman,Ranjit Banwait,Amy Sam,Diane Warren,Kenneth C. Anderson,Paul G. Richardson,Steven P. Treon,Jeffrey Matous +11 more
TL;DR: This study aimed to determine the safety and activity of panobinostat in patients with relapsed or relapsed/refractory Waldenstrom Macroglobulinemia with any prior lines of therapy, based on preclinical studies showing that panobinstat induces significant activity in cell lines and patient samples.
Journal ArticleDOI
Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
Jacalyn Rosenblatt,Irit Avivi,David Vasir,Lynne Uhl,Tami Katz,Poorvi Somaiya,Heidi Mills,Robin Joyce,James D. Levine,Vassiliki A. Boussiotis,Katarina Luptakova,Jon E. Arnason,Natalie Drummy,Carol Delaney,Emma Breault,Viki Held,Lina Bisharat,Nancy Giallombardo,Jamie Mortellite,Judith Wagoner,Michael Schickler,Rinat Rotem-Yehudar,Paul G. Richardson,Jacob P. Laubach,Kenneth C. Anderson,Nikhil C. Munshi,Jacob M. Rowe,Donald Kufe,David Avigan +28 more
Journal ArticleDOI
Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
Laurent Garderet,Jacob P. Laubach,Anne-Marie Stoppa,Parameswaran Hari,Michele Cavo,Heinz Ludwig,Maria-Victoria Mateos,Katarina Luptakova,Jianchang Lin,Godwin Yung,Helgi van de Velde,Deborah Berg,Philippe Moreau,Paul G. Richardson +13 more
TL;DR: Evaluated progression-free survival (PFS), duration of response (DOR) by depth of response and time to best response using data from the double-blind phase 3 TOURMALINE-MM1 trial of ixazomiblenalidomide-dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory MM.
Journal ArticleDOI
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Katja Weisel,Meletios A. Dimopoulos,Philippe Moreau,Münci Yağcı,Alessandra Larocca,Abraham S. Kanate,Filiz Vural,Nicola Cascavilla,Supratik Basu,Peter R. E. Johnson,Peter D. Byeff,Marek Hus,Paula Rodriguez-Otero,Ercan Muelduer,Pekka Anttila,Patrick Hayden,Maria-Theresa Krauth,Paulo Sérgio Lucio,Dina Ben-Yehuda,Larisa P. Mendeleeva,Shien Guo,Xin Yu,Lara Grote,Tsvetan Biyukov,Sujith Dhanasiri,Paul G. Richardson +25 more
TL;DR: Health-related quality of life results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.
Journal ArticleDOI
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.
Constantine S. Mitsiades,Luba Benimetskaya,Krishna Menon,Cinara Echart,Cecile Rouleau,Beverly A. Teicher,Antonio Palumbo,Mario Boccadoro,Massimo Iacobelli,Kenneth C. Anderson,Cy A. Stein,Paul G. Richardson +11 more
TL;DR: In vitro studies at DF concentrations achievable in vivo were conducted to evaluate effects on growth factors critical for tumor neovascularization and pathways regulating bioavailability of extracellular matrix (ECM)-resident growth factors, and suggest that DF can perturb bioavailability, expression and/or function of diverse positive regulators of neo-angiogenesis.